Presentations
Please note these are in order of the speaker’s last name and some speakers have opted not to share slides.
Alia Cibich
Improved survival after allogeneic HSCT over the last 35 years is driven by reduced non-relapse mortality: A Statewide Australian cohort analysis
Dr Heather Dunckley
Ethnicity, HLA and how this plays into donor sourcing and access
Dr Salvatore Fiorenza
Oral Abstract: Multidisciplinary TCT – A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial
No sharable file
Suchit Handa
National initiatives that support registry science and clinical quality
A/Prof Andrea Henden
Cell Therapies for Mantle Cell Lymphoma
Nancy Kim
Oral Abstract: Presidential – Health resource utilisation and costs of allogeneic hematopoietic stem cell transplantation: an Australian data linkage study
No sharable file
Dr John Kuruvilla
Emerging approaches in FL
Dr John Kuruvilla
The future of TCT in Lymphoma
Dr Kate Manos
Emerging therapeutic options in exposed double CLL
Gemma McErlean
Service equity for long term transplant survivors – a patient centred approach
Pending sharable file
A/Prof Mastura Monif
Complications of CAR-T: Neuro
No sharable file
A/Prof Olalekan O. Oluwole
Lunch’n’Learn: Building a Successful CAR-T Program
Dr Tim Prestidge
High Quality Care is Equitable Care
No sharable file
Dr Wael Saber
How CIBMTR and registry science lifts up our game
No sharable file
Prof Andrew Spencer
Looking Backwards in Myeloma: Myeloma treatment in octogenarians and beyond
No sharable file
Prof Judith Trotman
Debate: The role of transplant in lymphoma or is CAR-T the new standard – Role of Allo in low grade lymphoma (Negative)
No sharable file
Dr Robert Weinkove
Debate: The role of transplant in lymphoma or is CAR-T the new standard – Role of Allo in high grade lymphoma (Affirmative)
No sharable file
Leonie Wilcox
ANZTCT Registry update